Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer
Top Cited Papers
- 10 July 2009
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (20) , 3297-3302
- https://doi.org/10.1200/jco.2009.19.6410
Abstract
Purpose Population studies have suggested that metformin use in diabetic patients decreases cancer incidence and mortality. Metformin inhibits the growth of cancer cells in vitro and tumors in vivo...Keywords
This publication has 42 references indexed in Scilit:
- Important role of the LKB1–AMPK pathway in suppressing tumorigenesis in PTEN-deficient miceBiochemical Journal, 2008
- Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studiesPublished by Elsevier ,2008
- Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27Journal of Clinical Oncology, 2008
- The potential of antidiabetic thiazolidinediones for anticancer therapyExpert Opinion on Investigational Drugs, 2006
- Factors Affecting Sensitivity and Specificity of Screening Mammography and MRI in Women with an Inherited Risk for Breast CancerBreast Cancer Research and Treatment, 2006
- Metabolic syndrome as a prognostic factor for breast cancer recurrencesInternational Journal of Cancer, 2006
- Prognostic Value of Pathologic Complete Response After Primary Chemotherapy in Relation to Hormone Receptor Status and Other FactorsJournal of Clinical Oncology, 2006
- Overweight, obesity and cancer: epidemiological evidence and proposed mechanismsNature Reviews Cancer, 2004
- Insulin-like growth factors and neoplasiaNature Reviews Cancer, 2004
- Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. AdultsNew England Journal of Medicine, 2003